LONDON, March 18, 2026 /PRNewswire/ — Elliott Investment Management L.P. and Elliott Advisors (UK) Limited ("Elliott"), which advise funds that together have a significant investment in Mitsui O.S.K. Lines, Ltd. ("Mitsui O.S.K." or the "Company"), today issued the following statement:

Elliott’s investment in Mitsui O.S.K. Lines reflects our belief in the Company’s long track record of success in shipping and its standing as one of the largest diversified owners of oceangoing vessels globally. Despite this strong market position and high-quality assets, the market materially undervalues the business. We are a significant investor in Mitsui O.S.K. because we see an opportunity to work constructively with the Company to ensure its upcoming medium-term management plan is appropriately ambitious, to reframe how it is viewed by the market and to deliver the premium valuation it deserves.

About Elliott

Elliott Investment Management L.P. (together with its affiliates, "Elliott") manages approximately $79.8 billion of assets as of December 31, 2025. Founded in 1977, it is one of the oldest funds under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Investment Management L.P.

Media Contacts:

London
Stijn van de Grampel
Elliott Advisors (UK) Limited
T: +44 20 3009 1061
svdgrampel@elliottadvisors.co.uk

New York
Stephen Spruiell
Elliott Investment Management L.P.
T: +1 (212) 478-2017
sspruiell@elliottmgmt.com

Tokyo
Brett Wallbutton
Ashton Consulting
T: +81 (0) 3 5425-7220
b.wallbutton@ashton.jp

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery

BOSTON and HANGZHOU, China, May 11, 2026 /PRNewswire/ — Ranok Therapeutics, a clinical-stage biotechnology…

EnGenius Showcases Smarter AI and Cloud Networking Solutions at Interop Tokyo 2025

Cloud-Managed Wi-Fi 7 and AI Surveillance Solutions That Drive Innovation in Education,…

China Automotive Systems Record Earnings Per Share Rose 98% in the First Half of 2026

WUHAN, China, Aug. 13, 2026 /PRNewswire/ — China Automotive Systems, Inc. (NASDAQ:…